MOH vs NPCE: fair value comparison
Molina Healthcare, Inc. and NeuroPace, Inc. · Updated 2026-10-19
NPCE has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, MOH currently ranks higher by quality score.
| MOH | NPCE | |
|---|---|---|
| Verdict | Overvalued | No estimate yet |
| Last price | $180.85 | $12.24 |
| 12-month range | $122.65–$242.88 | $9.40–$19.29 |
| Rank by discount to fair value | #88 of 108 Healthcare | — |
| Rank by quality score | #165 of 301 Healthcare | #166 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Moderate | High |
| Margin trend | Expanding | Expanding |
| Revenue growth | Modest | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| 52-week position | The lower-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: MOH fair value analysis · NPCE fair value analysis